Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

August 19, 2016

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
RADIATION

Radical Radiotherapy (Conventional RT and SABR)

Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

OTHER

Non-investigational SACT

There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Trial Locations (19)

Unknown

UCLH, London

Belfast City Hospital, Belfast

Queen Elizabeth Hospital, Birmingham

Bristol Royal Infirmary, Bristol

Addenbrooke's Hospital, Cambridge

BEATSON, Glasgow

Royal Surrey County Hospital, Guildford

St James's University Hospital, Leeds

Leicester Royal Infirmary, Leicester

Guy's and St Thomas's Hospital, London

St Bart's Hospital, London

The Royal Marsden Hospital, London

Christie Hospital, Manchester

Clatterbridge Cancer Centre, Metropolitan Borough of Wirral

The James Cook University Hospital, Middlesbrough

Freeman Hospital, Newcastle

City Hospital, Nottingham

Weston Park Hospital, Sheffield

Southampton General Hospital, Southampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

lead

University College, London

OTHER